An observational study in Neurocognitive Disorders, sponsored by Central Hospital, Nancy, France. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Central Hospital, Nancy, France · Observational
The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.
Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance.
Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.
With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.
If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.
246 studies on the registry are indexed under Neurocognitive Disorders; 88 are open to participants now.
This study's enrollment of 20 is below the median of 165 across 93 observational studies indexed under Neurocognitive Disorders.
Browse Neurocognitive Disorders studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated for psychiatric reasons with neurocognitive disorders in the clinic, having consulted or being hospitalized at the psychotherapeutic center of Nancy between 01/01/2021 to 01/01/2024 and having undergone a flurodeoxyglucose positron emission tomography marked with fluorine 18 carried out in the course of care
Exclusion Criteria:
Neuro cognitive disorders and disorders of neurodegenerative origin in psychiatric population
Change of the diagnosis before the PET and after the PET
Time frame: one day
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France